A Dose Escalation Study or Org 10172 (Low Molecular Weight Heparinoid) in Stroke

No Thumbnail Available
Authors
Biller, J.
Massey, E.W.
Marler, J.R.
Adams, H.P.
Davis, J.N.
Bruno, A.
Henriksen, R.A.
Linhardt, Robert J.
Goldstein, L.B.
Alberts, M.
Issue Date
1989-01-01
Type
Article
Language
ENG
Keywords
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.
Description
Neurology, 39, 262-265
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Full Citation
A Dose Escalation Study or Org 10172 (Low Molecular Weight Heparinoid) in Stroke, J. Biller, E.W. Massey, J.R. Marler, H.P. Adams, J.N. Davis, A. Bruno, R.A. Henriksen, R.J. Linhardt, L.B. Goldstein, M. Alberts, C.T. Kisker, G.J. Toffol, C.S. Greenberg, K.J. Banwart, C. Bertels, D.W. Beck, M. Walker, H.N. Maganani, Neurology, 39, 262-265 (1989).
Publisher
Terms of Use
Journal
Volume
Issue
PubMed ID
DOI
ISSN
1526632X
283878
EISSN